Report
Almaty, 2016
Authors: Ganina L.Yu., head of epidemiology department, Republican AIDS Center (RAC), Yelizaryeva A. V., epidemiologist, RAC, Kaspirova А. А., head of epidemiology department, Aktobe Oblast AIDS center, IvakinV.Yu., deputy regional director for strategic information, ICA...P, KryukovaV.А., Strategic Information Specialist for Kazakhstan, ICAP, Abishev A. T., acting director general, RAC.
Edited by Saparbekov M. K., Doctor of Medical Science, Professor, Head of the Department of Epidemiology and Hygiene Faculty of Medicine – GSPH KazNU n.a. Al-Farabi, Almaty c.
more
In Vietnam, most of the examination and treatment facilities are facing with of spread of bacteria resistant to many antibiotics. The level and speed of drug resistance are increasing, at alarming level. The burden of drug resistance is increasing due to the increasing cost of treatment, prolonged t...reatment,. That will affect patients’ health, community and social development. In the future, many
nations will be able to face the possibility of having no effective drugs to treat infectious diseases if they do not make appropriate interventions.
more
Training materials for healthcare workers
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t...o protect populations from malaria (chemoprevention), while considering relevant measures of efficacy and the safety data needed to support WHO policy recommendations.
more
Chagas disease affects 8-10 million people worldwide, mainly in Latin America. The current therapy for Chagas disease is limited to nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease but with severe side effects. Therefore, there is an unmet need for new... drugs and for the exploration of innovative approaches which may lead to the discovery of new effective and safe drugs for its treatment.
more
HIV & AIDS Treatment in Practice No.202
Journal of Pulmonary & Respiratory Medicine 6: 326. doi:10.4172/2161-105X.1000326
12-13 December 2016
Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016
AIDSTAR-One | CASE STUDY SERIES November 2012
Regional action plan 2019-2023
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Ra...pid Communication is released in advance of updated WHO consolidated guidelines expected later in 2022, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.
more
Report by the Director-General. 75th World health assembly 25 April 2022